Ariad Pharmaceutical (ARIA +0.7%) says its corporate partner MolecularMD has voluntarily...
Tuesday, September 18, 2012, 2:43 PM ETAriad Pharmaceutical (ARIA +0.7%) says its corporate partner MolecularMD has voluntarily withdrawn its pre-marketing approval application for BCR-ABL T3151, a mutation test to diagnose certain forms of leukemia that was to be used in conjunction with ARIA's ponatinib BCR-ABL inhibitor. The FDA recently informed the company that the test is no longer considered to be a companion diagnostic test for ponatinib.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles